Astrazeneca Pharma India Ltd - ASTRAZENECA PHAR Share Price

Sector: Pharmaceuticals | ISIN: INE203A01020
₹ 4,503.25 (0.80%) icon29 Sep, 2023, 3:56:12 PM

Astrazeneca Pharma India Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/29/2023 3:56:12 PM

    ₹ 4503.25 35.65 0.80
  • Open
  • ₹ 4,450.25
  • Prev. Close
  • ₹ 4,467.6
  • Turnover(Lac.)
  • ₹ 259
  • Day's High
  • ₹ 4,513.9
  • Day's Low
  • ₹ 4,429.75
  • 52 Week's High
  • ₹ 4,640
  • 52 Week's Low
  • ₹ 2,911
  • Book Value
  • ₹ 257.02
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 11,258.13
  • P/E
  • 68.31
  • EPS
  • 65.94
  • Divi. Yield
  • 0.36

Astrazeneca Pharma India Ltd Corporate Actions

04 Aug , 2023

12:00 AM

04 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

22 Jul , 2023

12:00 AM

AGM

Announcement date: 22 Jul , 2023

View Details

30 May , 2023

12:00 AM

Dividend

Dividend amount: 16
Announcement date: 30 May , 2023

View Details

22 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2023

12:00 AM

14 Dec , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Oct , 2022

12:00 AM


Astrazeneca Pharma India Ltd News and Update

Image not found
  • 1 day ago |
  • 8:36 PM

The company signed a power-purchase agreement with GRIDCO, an Odisha state power undertaking, for the purchase of 400 MW generated through thermal power plants in Jharsuguda and Sambalpur.

Image not found
  • IIFL News Service |
  • 1 day ago |
  • 8:36 PM
Image not found
  • IIFL News Service |
  • 1 day ago |
  • 8:36 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Astrazeneca Pharma India Ltd SHAREHOLDING SNAPSHOT
30 September , 2023 | 06:36 PM

PROMOTER - TOTAL75.00%

Indian: 0.00%

Foreign: 75%

NON-PROMOTER - TOTAL 25.00%

Institutions: 4.60%

Non-Institutions: 20.40%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Astrazeneca Pharma India Ltd FINANCIALS

No Data Available To Display Chart

Astrazeneca Pharma India Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Astrazeneca Pharma India Ltd

  • Narayan K Seshadri
  • Chairman & Independent Directo
  • Revathy Ashok
  • Non-Exec. & Independent Dir.
  • Rajesh Marwaha.
  • Whole Time Director & CFO
  • Weiying Sarah Wang
  • Non Executive Director
  • Ankush Nandra
  • Non Executive Director
  • Shilpa Divekar Nirula
  • Non-Exec. & Independent Dir.
  • Sanjeev Panchal
  • Managing Director

Summary

AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has... Read More


Reports by Astrazeneca Pharma India Ltd


Reports by Astrazeneca Pharma India Ltd

Company FAQ

No Record Found